ACE2 and COVID-19: Although we did not find any evidence of chronic therapy influencing ACE2 or TMPRSS2 expression (Supplementary Fig. 2), angiotensin receptor blockers were significantly more frequent among cases, suggesting an impact on COVID-19 severity.